David J. Benjamin/X
May 27, 2025, 05:38
David J. Benjamin: Precision Medicine in Genitourinary Oncology – Are We Pivoting Towards Imprecision?
David J. Benjamin, Medical Oncologist at the Hoag Family Cancer Institute, shared an article on X:
“Is the field of genitourinary oncology pivoting away from precision medicine – and towards imprecision?
In BJU International, Arash Rezazadeh and I cite two recent examples of TALAPRO-2 (for metastatic hormone resistant prostate cancer) and EV-302 (for advanced urothelial carcinoma).
Both had conference updates suggesting no role for biomarkers despite pre-clinical and trial data suggesting otherwise. This is timely given the FDA ODAC’s vote against TALAPRO-2 last week.
Our field is at a critical juncture in deciding whether to use biomarkers to pair the right treatment with the right individual.”
Title: Precision Medicine in Genitourinary Oncology – Are We Pivoting Towards Imprecision?
Authors: David J. Benjamin, Arash Rezazadeh Kalebasty
Read The Full Article at BJUI.
More posts featuring David Benjamin.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:28
May 29, 2025, 16:50